Sicca Syndrome (Investigational Adjunct)
Investigational adjunct for sicca (dry eye and dry mouth) symptoms; ophthalmologic lubricants, salivary stimulants (pilocarpine, cevimeline), and rheumatology workup remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for sicca syndrome / Sjogren-related dryness. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No controlled trial in dry eye or dry mouth was identified; the only clinical reports found are uncontrolled Russian series in chronic sialadenitis and sialadenosis, which found leech therapy ineffective in Sjogren-associated parotitis. Evidence-based first-line management is artificial tears and oral lubrication, punctal occlusion for refractory ocular dryness, pilocarpine or cevimeline for sialagogue effect, cyclosporine ophthalmic emulsion, lifitegrast ophthalmic solution, and for Sjogren syndrome with systemic involvement, hydroxychloroquine and other DMARDs as guided by rheumatology.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Dry-eye worsening from facial placement near the eyes
- Risk of corneal exposure injury if eyelid edema increases temporarily
- Who should not consider this
- Patients without confirmed diagnosis — Sjogren needs serology and possibly minor salivary gland biopsy
- Patients who have not tried artificial tears, cyclosporine ophthalmic, and pilocarpine
- Patients with active Sjogren-related lymphoma or other systemic complications
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Has my dryness been worked up for Sjogren syndrome (anti-Ro/SSA, anti-La/SSB, minor salivary gland biopsy)?
- Have I been evaluated by rheumatology for systemic involvement?
- Have I tried artificial tears, cyclosporine ophthalmic, pilocarpine, and punctal plugs?
- What is the published evidence base for leeches in sicca syndrome?
- What is the risk to my already-dry eyes from facial placement?
- How will my Sjogren-related lymphoma risk be monitored?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Severe eye pain, vision change, or new ulceration (corneal complication)
- New lymph node enlargement, salivary gland mass, or systemic symptoms (Sjogren-related lymphoma risk)
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for sicca/Sjogren — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace established ocular and oral lubricants, sialagogues, or DMARDs.
- It does not modify the underlying autoimmune process.
- It does not lower the Sjogren-associated lymphoma risk that requires lifelong surveillance.
- No controlled trial in this condition was identified; the only clinical reports found are uncontrolled Russian series in chronic sialadenitis and sialadenosis, which found leech therapy ineffective in Sjogren-associated parotitis.
Safety cross-references
Clinical Profile
- Category
- ENT
- ICD-10
- M35.00, M35.01, H04.121
- Safety tier
- High
Evidence Summary
Sicca syndrome (dryness of eyes and mouth) is a clinical description that may be primary (Sjogren disease) or secondary to medications, aging, autoimmune disease, or radiation. Workup includes ophthalmologic evaluation with Schirmer test, salivary flow assessment, autoantibodies (anti-Ro/SSA, anti-La/SSB), and rheumatology referral when Sjogren is suspected. Evidence-based management: preservative-free ocular lubricants, punctal plugs, cyclosporine or lifitegrast ophthalmic drops, oral pilocarpine or cevimeline for xerostomia, saliva substitutes, and treatment of underlying autoimmune disease. Two Russian reports indexed in PubMed (Abal'masov 2003, 20 patients; Abal'masov 2004, 39 patients) treated chronic sialadenitis and sialadenosis with leeches and reported improvement in many patients, but hirudotherapy was ineffective in patients with chronic parenchymatous parotitis associated with Sjogren syndrome. No study in dry eye and no controlled trial was identified. The face, salivary gland, and lacrimal regions are uniquely high-risk for placement.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active rheumatologic flare
- Immunomodulatory therapy with significant immunosuppression
- Facial, parotid, or lacrimal placement
- Sjogren-associated lymphoma not worked up
- Concurrent active dental or sinus pathology
Related Conditions
Dry Eye Syndrome
Investigational use for dry eye disease; no clinical study of leech therapy was identified, and the proposed meibomian-gland mechanism is hypothetical.
Chronic Glossitis (Investigational Adjunct)
Highly investigational adjunct for chronic glossitis; no study in glossitis found; treating nutritional, infectious or allergic causes remains primary.
Cutaneous Lichen Planus (Localized)
Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.
Chronic Rhinosinusitis
Investigational use for chronic rhinosinusitis; no clinical study of leech therapy for this condition was identified, and the rationale is mechanistic.